Launch Readiness Guide for MedTech Leaders

A product can clear a regulatory milestone, impress clinicians in a demonstration, and still miss its commercial targets. The failure rarely begins on launch day. It begins months earlier, when teams mistake product completion for market readiness. This launch readiness guide is built for MedTech and HealthTech leaders who need to turn an approved or nearly approved technology into customer adoption, revenue, and a platform for sustained growth.

A credible launch is not a marketing event. It is an operating decision: can your organization consistently explain the value, support the buyer, train the user, manage the evidence, and deliver on the promise made by the sales team? If the answer varies by department, the launch is not ready.

Launch readiness is a commercial discipline

Healthcare markets expose gaps that other industries can sometimes absorb. A hospital value analysis committee may require economic evidence that marketing has not prepared. A clinician may need workflow training before using the technology with patients. A distributor may ask for a selling story, target-account criteria, and escalation procedures that do not yet exist. A customer support issue during the first installation can weaken an account before the second sales call occurs.

The central challenge is coordination. Regulatory, clinical, product, marketing, sales, operations, and customer success often work to different timelines and definitions of success. Regulatory may view launch as permissible market entry. Sales may view it as a quota-carrying opportunity. Customers judge it by whether the product solves a meaningful problem with reasonable clinical, operational, and financial risk.

Executive leadership must establish one definition of readiness that connects all three perspectives. The goal is not to delay launch until every uncertainty disappears. That is neither realistic nor commercially wise. The goal is to identify the uncertainties that could prevent adoption, determine who owns them, and decide which risks are acceptable for a controlled market entry.

Start the launch readiness guide with market proof

The first question is not, “Are we ready to sell?” It is, “What evidence tells us the market will buy, use, and continue using this product?” A compelling technology can still struggle if the target customer, use case, buying process, or economic case is poorly defined.

Begin with a precise market-entry hypothesis. Name the initial customer segment, the clinical or operational problem it experiences, the stakeholder who feels that problem most acutely, and the economic buyer who can authorize change. In complex healthcare organizations, these may be four different people. A surgeon, nursing leader, supply chain executive, IT security team, and CFO can each influence adoption for different reasons.

Your launch plan should show how the product creates value for each relevant stakeholder without trying to be everything to everyone. Clinical outcomes may lead the conversation in one segment. Workflow efficiency, risk reduction, reimbursement potential, or cost avoidance may lead in another. This depends on the product category and care setting, but the commercial team needs a clear hierarchy of messages rather than a long list of features.

Market proof also requires honest competitive analysis. Identify the current standard of care, including the option to do nothing. A new device does not compete only with comparable devices. It may compete with an established procedure, a manual workaround, an incumbent contract, limited capital budgets, or clinician reluctance to change practice. If the sales organization cannot explain why a customer should change now, enthusiasm at a trade show will not translate into purchase orders.

Align the five readiness workstreams

A launch plan becomes actionable when leadership can see the workstreams, the dependencies between them, and the accountable owner for each decision. The following areas should be reviewed together, not as isolated checklists:

• Regulatory and quality readiness: Confirm the approved claims, labeling, promotional boundaries, complaint-handling process, adverse-event responsibilities, training requirements, and any market-specific restrictions. Commercial pressure must never encourage claims that the evidence or clearance does not support.

• Market access and economic readiness: Define reimbursement status, coding assumptions, pricing logic, budget impact, contracting requirements, and the health-economic evidence needed for target accounts. A clinically valuable product may still stall when no one can explain how the customer pays for it.

• Sales readiness: Equip the team with account profiles, qualification criteria, stakeholder maps, discovery questions, objection handling, competitive positioning, sales tools, and a realistic sales-cycle forecast. A sales team needs more than a product presentation. It needs a repeatable method for advancing opportunities.

• Customer implementation readiness: Establish installation steps, onboarding expectations, clinical education, technical support coverage, service-level commitments, and escalation paths. The handoff from sales to implementation is one of the highest-risk moments in a healthcare launch.

• Measurement and governance readiness: Set leading and lagging indicators, meeting cadence, decision rights, and a process for converting field feedback into action. Early revenue matters, but so do qualified pipeline, conversion by stage, time to first use, utilization, training completion, support trends, and renewal or reorder signals.

The trade-off is straightforward. Building every asset before launch can consume time and capital. Launching with too little structure can create rework, damage credibility, and make it difficult to distinguish a weak market from weak execution. A phased launch often provides the better answer: begin with a defined customer cohort, controlled geography, or limited indication, then expand as the organization proves its model.

Make the sales motion credible in the field

The commercial team is where the company’s strategy meets customer reality. That makes sales readiness more than hiring representatives or setting a revenue target. Reps, channel partners, clinical specialists, and sales leaders must understand the product deeply enough to conduct a credible conversation while staying within approved claims and appropriate clinical boundaries.

Start by defining the buyer journey. How does an account move from awareness to evaluation, internal approval, procurement, implementation, and recurring use? At each stage, identify the customer question, the evidence required, the internal resource responsible, and the next commitment needed to move forward. This prevents the common problem of sending a generic brochure when the account actually needs a clinical champion, economic analysis, cybersecurity documentation, or implementation plan.

Training should be scenario-based. Ask a salesperson to explain the value proposition to a service-line leader, then ask a clinical specialist to respond to a physician concerned about workflow disruption. Test whether a channel partner knows when to bring in technical support. Role-play objections involving price, incumbent suppliers, evidence quality, and procurement delays. Product knowledge matters, but commercial confidence comes from practicing the conversations that determine access and adoption.

Compensation and performance management should reinforce the launch strategy. If leadership needs early reference accounts and high-quality utilization data, rewarding only booked revenue can create the wrong behavior. In some launches, a smaller number of well-supported accounts is more valuable than broad but shallow placement. The appropriate balance depends on capital availability, product complexity, service capacity, and the speed at which evidence can be generated.

Treat customer success as part of market entry

A signed contract is not proof of market adoption. In MedTech and HealthTech, the first weeks after purchase often determine whether a customer becomes a reference, a reordering account, or a source of preventable friction.

Before launch, map the complete customer experience from contracting through training, first use, technical support, data reporting, and executive follow-up. Specify what customers should expect and what your organization must deliver. When responsibilities are vague, sales blames operations, operations blames the customer, and the customer experiences the company as unprepared.

Early accounts deserve structured executive attention. Not because every issue should be escalated, but because first customers provide the most valuable evidence about onboarding, messaging, workflow fit, and support demand. Capture their feedback in a disciplined format. Separate isolated requests from repeatable patterns. Then give a cross-functional launch team authority to decide what changes now, what gets tested next, and what requires a longer product or process investment.

Use a launch command center, not status meetings

Launch governance should produce decisions, not presentations. Establish a cross-functional command center with a single executive sponsor and named leaders for regulatory, commercial, clinical, operations, and customer support. During the first months of market entry, meet frequently enough to resolve blockers before they become customer problems.

Each meeting should review a concise set of facts: pipeline quality, account progression, implementation status, training completion, customer issues, field objections, competitive activity, and forecast risk. The purpose is to connect signals. For example, slow sales conversion may reflect pricing, but it may also reveal that the buyer does not see a clear implementation path. Rising support tickets may signal inadequate training, product usability issues, or an account profile that is not yet appropriate.

Leaders should resist two temptations. The first is declaring victory based on a few early wins. The second is abandoning the strategy after normal launch friction. Use evidence to distinguish a correctable execution problem from a flawed market assumption. That is how a launch becomes an informed growth engine rather than an expensive announcement.

The companies that build durable market share are not necessarily the first to announce a new technology. They are the ones that enter with clear accountability, learn faster than competitors, and earn customer confidence through every interaction. For leaders under pressure to grow, launch readiness is the moment to replace optimism with disciplined commercial execution.